Medicina Clínica, Journal Year: 2023, Volume and Issue: 162(9), P. 448 - 454
Published: Dec. 30, 2023
Nature Reviews Methods Primers, Journal Year: 2023, Volume and Issue: 3(1)
Published: Aug. 17, 2023
Language: Английский
Citations
74
Science China Chemistry, Journal Year: 2024, Volume and Issue: 67(4), P. 1060 - 1096
Published: March 12, 2024
Language: Английский
Citations
65
Science China Life Sciences, Journal Year: 2023, Volume and Issue: 66(10), P. 2329 - 2341
Published: June 1, 2023
Language: Английский
Citations
31
Acta Pharmaceutica Sinica B, Journal Year: 2023, Volume and Issue: 13(12), P. 5074 - 5090
Published: Sept. 1, 2023
Autologous cancer vaccine that stimulates tumor-specific immune responses for personalized immunotherapy holds great potential tumor therapy. However, its efficacy is still suboptimal due to the immunosuppressive microenvironment (ITM). Here, we report a new type of bacteria-based autologous by employing calcium carbonate (CaCO3) biomineralized Salmonella (Sal) as an in-situ producer and systematical ITM regulator. CaCO3 can be facilely coated on Sal surface with ionophore A23187 co-loading, such biomineralization did not affect bioactivities bacteria. Upon intratumoral accumulation, shell was decomposed at acidic attenuate acidity, accompanied release Ca2+/A23187. Specifically, served inducing cells' immunogenic cell death (ICD) promoting gap junction formation between cells dendritic (DCs) promote antigen presentation. Ca2+, other hand, internalized into various types aid synergized systematically regulate system, including DCs maturation, macrophages polarization, T activation. As result, bio-vaccine achieved remarkable against both primary metastatic tumors eliciting potent anti-tumor immunity full biocompatibility. This work demonstrated bioengineered bacteria bio-active vaccines enhanced immunotherapy.
Language: Английский
Citations
17
Advanced Science, Journal Year: 2023, Volume and Issue: 10(35)
Published: Oct. 27, 2023
Abstract Epstein‐Barr virus (EBV) is associated with various malignancies and infects >90% of the global population. EBV latent proteins are expressed in numerous EBV‐associated cancers contribute to carcinogenesis, making them critical therapeutic targets for these cancers. Thus, this study aims develop mRNA‐based vaccines that express T‐cell‐epitope‐rich domain truncated EBV, including truncatedlatent membrane protein 2A (Trunc‐LMP2A), nuclear antigen 1 (Trunc‐EBNA1), Trunc‐EBNA3A. The effectively activate both cellular humoral immunity mice show promising results suppressing tumor progression improving survival time tumor‐bearing mice. Furthermore, it observed forms antigens, Trunc‐LMP2A, Trunc‐EBNA1, Trunc‐EBNA3A, more effective than full‐length antigens activating antigen‐specific immune responses. In summary, findings demonstrate effectiveness targeting providing new treatment options
Language: Английский
Citations
17
ACS Biomaterials Science & Engineering, Journal Year: 2023, Volume and Issue: 9(11), P. 5999 - 6023
Published: Nov. 3, 2023
The use of cancer vaccines is considered a promising therapeutic strategy in clinical oncology, which achieved by stimulating antitumor immunity with tumor antigens delivered the form cells, peptides, viruses, and nucleic acids. ideal vaccine has many advantages, including low toxicity, specificity, induction persistent immune memory to overcome heterogeneity reverse immunosuppressive microenvironment. Many have entered trials for variety cancers, melanoma, breast cancer, lung others. However, challenges, single antigen targeting, weak immunogenicity, off-target effects, impaired response, hindered their broad translation. In this review, we introduce principle action, components (including adjuvants), classification (according applicable objects preparation methods) vaccines, summarize delivery methods review theoretical research progress vaccines. We also present new insights into technologies, platforms, applications as well an understanding potential next-generation preventive providing broader perspective future design.
Language: Английский
Citations
16
Expert Opinion on Biological Therapy, Journal Year: 2024, Volume and Issue: 24(4), P. 269 - 284
Published: April 2, 2024
Introduction Colorectal cancer (CRC) is the second most lethal malignancy worldwide. Immune checkpoint inhibitors (ICIs) benefit only 15% of patients with mismatch repair-deficient/microsatellite instability (dMMR/MSI) CRC. The majority are not suitable due to insufficient immune infiltration. Cancer vaccines a potential approach for inducing tumor-specific immunity within solid tumor microenvironment.
Language: Английский
Citations
5
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: March 21, 2024
Gastric cancer is one of the cancers with increasing incidence and ranks fourth globally among most frequent causes cancer-related mortality. Early gastric often asymptomatic or presents atypical symptoms, majority patients present advanced disease upon diagnosis. Brain metastases are in approximately 1% at time diagnosis, which significantly contributed to overall mortality worldwide. Conventional therapies for brain remain limited median survival only 8 months cases. Recent studies have improved our understanding molecular mechanisms underlying metastases, immunotherapy has become an important treatment option combination radiotherapy, chemotherapy, targeted therapy surgery. This review aims provide insight into cellular processes involved discuss diagnostic approaches, evaluate integration immune checkpoint inhibitors prognosis, explore predictive value biomarkers immunotherapy.
Language: Английский
Citations
4
Science China Life Sciences, Journal Year: 2024, Volume and Issue: 67(8), P. 1648 - 1665
Published: April 25, 2024
Language: Английский
Citations
4
Science China Life Sciences, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 4, 2024
Language: Английский
Citations
4